Gabriele Escherich

Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

B-cell acute lymphoblastic leukemia (B-ALL) with high-hyperdiploidy (HHD) represents the most prevalent genetic subtype of childhood ALL. This retrospective international study aimed to identify the HHD subgroup(s) having both the highest proportion of B-ALL cases and the best outcome.Data from 11,530 B-ALL patients, including 3,231 with HHD-B-ALL, treated between 1998 and 2018 in eight trials from seven international Berlin-Frankfurt-Münster Group members were analyzed. Eight HHD subgroups – including double and triple trisomies, trisomy 18, UK-good-risk (UK-GR) profile, and four different modal chromosome number (MCN) categories – were evaluated for 5-year event-free survival (EFS), overall survival, and relapse. Each subgroup was ranked by outcome measures and prevalence within the B-ALL trial cohorts.HHD frequency ranged from 19–35%. MCN 54–67 and UK-GR profile achieved the lowest overall ranking scores corresponding to the largest (up to 28% for MCN 54–67 and 26% for UK-GR among total B-ALL trial cohorts) and best HHD subgroups (EFS ranged from 80.5–92.8% for MCN 54–67 and 80.5–93.5% for UK-GR).Both an MCN of 54–67 and UK-GR profile define large, reproducible subgroups of HHD B-ALL with good prognosis. They represent strong candidates for risk-stratification of treatment de-intensification trials in the modern immunotherapy era.

Year:

2025

Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this disease. We found age and genetic drivers were significantly associated with outcome. γδ T-ALL diagnosed in children under 3 years of age was extremely high-risk and enriched for genetic alterations that result in both LMO2 activation and STAG2 inactivation. Mechanistically, using patient samples and isogenic cell lines, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer–promoter looping, resulting in deregulation of gene expression associated with T-cell differentiation. High-throughput drug screening identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which can be targeted by poly(ADP-ribose) polymerase inhibition. These data provide a diagnostic framework for classification and risk stratification of pediatric γδ T-ALL. Significance: Patients with acute lymphoblastic leukemia expressing the gamma delta T-cell receptor under 3 years old or measurable residual disease ≥1% at end of induction showed dismal outcomes and should be classified as having high-risk disease. The STAG2/LMO2 subtype was enriched in this very young age group. STAG2 inactivation may perturb chromatin conformation and cell differentiation and confer vulnerability to poly(ADP-ribose) polymerase inhibition.

Year:

2024

Acute lymphoblastic leukemia (ALL) with fusions of ABL-class tyrosine kinase genes other than BCR::ABL1 occurs in ∼3% of children with ALL. The tyrosine kinase genes involved in this BCR::ABL1-like (Ph-like) subtype include ABL1, PDGFRB, ABL2, and CSF1R, each of which has up to 10 described partner genes. ABL-class ALL resembles BCR::ABL1-positive ALL with a similar gene expression profile, poor response to chemotherapy, and sensitivity to tyrosine kinase inhibitors (TKIs). There is a lack of comprehensive data regarding TKI sensitivity in the heterogeneous group of ABL-class ALL. We observed variability in TKI sensitivity within and among each ABL-class tyrosine kinase gene subgroup. We showed that ALL samples with fusions for any of the 4 tyrosine kinase genes were relatively sensitive to imatinib. In contrast, the PDGFRB-fused ALL samples were less sensitive to dasatinib and bosutinib. Variation in ex vivo TKI response within the subset of samples with the same ABL-class tyrosine kinase gene was not associated with the ALL immunophenotype, 5′ fusion partner, presence or absence of Src-homology-2/3 domains, or deletions of IKZF1, PAX5, or CDKN2A/B. In conclusion, the tyrosine kinase gene involved in ABL-class ALL is the main determinant of TKI sensitivity and relevant for specific TKI selection.

Year:

2024

Background The prognosis of children with acute lymphoblastic leukemia (ALL) has improved considerably over the past five decades. However, to achieve cure in patients with refractory or relapsed disease, novel treatment options are necessary. Methods In the multicenter trial Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (CoALL)08‐09, one additional treatment element consisting of the rarely used chemotherapeutic agent amsacrine combined with etoposide and methylprednisolone (AEP) (amsacrine 2 × 100 mg/m 2 , etoposide 2 × 500 mg/m 2 , and methylprednisolone 4 × 1000 mg/m 2 ) was incorporated into the first‐line treatment of pediatric patients with poor treatment responses at the end of induction (EOI), measured by minimal residual disease (MRD). These patients were stratified into a high‐risk intensified arm (HR‐I), including an AEP element at the end of consolidation. Patients with induction failure (IF), that is, with lack of cytomorphological remission EOI, were eligible for hematopoietic stem cell transplantation (HSCT) after remission had been reached. These patients received AEP as a part of their MRD‐guided bridging‐to‐transplant treatments. Results A significant improvement in probability of overall survival (pOS) was noted for the CoALL08‐09 HR‐I patients compared to MRD‐matched patients from the preceding CoALL07‐03 trial in the absence of severe or persistent treatment‐related toxicities. Relapse rate and probability of event‐free survival (pEFS) did not differ significantly between trials. In patients with IF, stable or improved MRD responses after AEP were observed without severe or persistent treatment‐related toxicities. Conclusion In conclusion, AEP is well tolerated as a component of the HR treatment and is useful in bridging‐to‐transplant settings.

Year:

2022

Collaborators (36)

Shondra Pruett-Miller

Associate Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Mariko Eguchi

Profesor

Ehime University Graduate School of Medicine

JAPAN
View details

Chi Kong Li

Professor

The Chinese University of Hong Kong (CUHK)

HONG KONG
View details

Martin Schrappe

-

GERMANY
View details

riccardo masetti

Assistant Professor

University of Bologna

ITALY
View details

Kjeld Schmiegelow

-

DENMARK
View details

Sarah Tasian

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Hanne Vibeke Hansen Marquart

Chief Physician; MD, PhD, Clinical Associate Professor

Copenhagen University Hospital

DENMARK
View details

Allen Eng Juh Yeoh

National University of Singapore (NUS)

SINGAPORE
View details

Atsushi Manabe

Professor

Hokkaido University

JAPAN
View details

Valentino Conter

-

ITALY
View details

John Choi

The University of Alabama

UNITED STATES
View details

Anthony Moorman

Professor of Genetic Epidemiology

Newcastle University

UNITED KINGDOM
View details

Franco Locatelli

Full Professor of Pediatrics

Catholic University of the Sacred Heart

ITALY
View details

Steven Kornblau

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Junko Takita

教授 / Professor

Kyoto University

JAPAN
View details

Szymon Skoczen

Associated Professor

Uniwersytet Jagiellonski Collegium Medicum

POLAND
View details

Kathryn Roberts

St. Jude Children's Research Hospital

UNITED STATES
View details

David Teachey

Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Daisuke Tomizawa

Head

National Center For Child Health and Development

JAPAN
View details

Cheng Cheng

Professor

St Jude Grade School of Biomedical Sciences

UNITED STATES
View details

Arndt Borkhardt

Prof

Heinrich Heine University Düsseldorf

GERMANY
View details

Motohiro Kato

-

JAPAN
View details

Judith Boer

Senior researcher

Princess Maxima Center

NETHERLANDS
View details

Takao Deguchi

Head of Division

National Center For Child Health and Development

JAPAN
View details

Monique den Boer

Group Leader

Princess Maxima Center

NETHERLANDS
View details

Ching-Hon Pui

Fahad Nasser Al-Rashid Chair of Leukemia Research

St. Jude Children's Research Hospital

UNITED STATES
View details

Andrew Moore

Associate Professor

University of Queensland

AUSTRALIA
View details

Ilaria Iacobucci

Principal Scientist

St. Jude Children's Research Hospital

UNITED STATES
View details

Masatoshi Takagi

Tokyo Medical and Dental University

JAPAN
View details

Zhaohui Gu

Assistant Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Paul G Thomas

Professor

Fred Hutch Cancer Center

UNITED STATES
View details

Andishe Attarbaschi

Medical University of Vienna

AUSTRIA
View details

Amir Enshaei

Senior Lecturer

Newcastle University

UNITED KINGDOM
View details

Charles Mullighan

Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center

St. Jude Children's Research Hospital

UNITED STATES
View details

Rishi Kotecha

Professor

Telethon Kids Institute

AUSTRALIA
View details